--- title: "PAVmed Reports Q1 2026 Results and Business Update" type: "News" locale: "en" url: "https://longbridge.com/en/news/286567652.md" description: "PAVmed reported Q1 2026 results, highlighting a simplified capital structure and stronger balance sheet. The company advanced its medical device portfolio and reported $1.3 million in EsoGuard revenue. For the quarter, PAVmed had operating expenses of $8.1 million and a GAAP net loss of $7.0 million. Analysts rate PAVM stock as a Buy with a $65.00 price target, though concerns about financial fundamentals persist. PAVmed operates in medical technology, focusing on early disease detection and cancer care." datetime: "2026-05-15T12:29:16.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286567652.md) - [en](https://longbridge.com/en/news/286567652.md) - [zh-HK](https://longbridge.com/zh-HK/news/286567652.md) --- # PAVmed Reports Q1 2026 Results and Business Update ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks The latest announcement is out from PAVmed ( (PAVM) ). On May 15, 2026, PAVmed reported first-quarter 2026 results and a business update, highlighting a simplified capital structure, stronger balance sheet, and ongoing evaluation of acquisition opportunities to support long-term growth. The company advanced its relaunched medical device portfolio under medtech executive Joseph Virgilio, including the PortIO vascular access device and Duke-licensed esophageal imaging technology, while Veris progressed its implantable physiological monitor toward an FDA 510(k) submission and deepened commercial engagement with Ohio State’s James Cancer Hospital. Subsidiary Lucid Diagnostics generated $1.3 million in first-quarter 2026 EsoGuard revenue from 3,177 tests, bolstered liquidity with a $17 million equity raise to end the quarter with $45 million in pro forma cash, and showcased EsoGuard and EsoCheck at Digestive Disease Week ahead of a key guideline update. For the quarter ended March 31, 2026, PAVmed reported operating expenses of $8.1 million, a GAAP net loss attributable to common stockholders of $7.0 million, a non-GAAP adjusted loss of $1.9 million, and cash and cash equivalents of $6.5 million, underscoring a narrower adjusted loss profile and improved liquidity that support continued commercialization and development efforts. The most recent analyst rating on (PAVM) stock is a Buy with a $65.00 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page. **Spark’s Take on PAVM Stock** According to Spark, TipRanks’ AI Analyst, PAVM is a Neutral. The score is held down primarily by weak financial fundamentals—persistent cash burn, negative gross profit, and very large/volatile losses—alongside bearish technical trends with the stock below key moving averages. These risks are partially offset by relatively positive execution and funding updates from the earnings call and subsequent corporate event, plus progress toward potential reimbursement and commercialization milestones. To see Spark’s full report on PAVM stock, click here. **More about PAVmed** PAVmed Inc. is a diversified commercial-stage medical technology company operating across the medical device, diagnostics, and digital health sectors, with subsidiaries Lucid Diagnostics and Veris Health. Its portfolio includes the EsoGuard Esophageal DNA Test, implantable intraosseous vascular access devices, endoscopic esophageal imaging technologies, and an implantable physiological monitor, targeting early disease detection, cancer care, and minimally invasive patient management. **Average Trading Volume:** 22,290 **Technical Sentiment Signal:** Sell **Current Market Cap:** $41.17M ### Related Stocks - [PAVM.US](https://longbridge.com/en/quote/PAVM.US.md) - [XHE.US](https://longbridge.com/en/quote/XHE.US.md) - [IHI.US](https://longbridge.com/en/quote/IHI.US.md) - [LUCD.US](https://longbridge.com/en/quote/LUCD.US.md) - [PAVMZ.US](https://longbridge.com/en/quote/PAVMZ.US.md) ## Related News & Research - [Analyst Reaffirms Buy on PAVmed, Citing Oncology Platform Momentum and Partnerships; Price Target Maintained at $16](https://longbridge.com/en/news/286945953.md) - [embecta Completes Acquisition of Owen Mumford Holdings Limited](https://longbridge.com/en/news/286571686.md) - [BUZZ-Dexcom climbs on plans to revamp board panel](https://longbridge.com/en/news/286583878.md) - [Stryker Buys Amplitude Vascular Systems For Upto $835 Mln To Expand Vascular Treatment Business](https://longbridge.com/en/news/286889480.md) - [How Chubb’s (CB) New Canada Cancer Coverage Launch Could Reframe Its Health Benefits Strategy](https://longbridge.com/en/news/286787301.md)